ECSP21044840A - Vectores virales recombinantes y ácidos nucleicos para producirlos - Google Patents

Vectores virales recombinantes y ácidos nucleicos para producirlos

Info

Publication number
ECSP21044840A
ECSP21044840A ECSENADI202144840A ECDI202144840A ECSP21044840A EC SP21044840 A ECSP21044840 A EC SP21044840A EC SENADI202144840 A ECSENADI202144840 A EC SENADI202144840A EC DI202144840 A ECDI202144840 A EC DI202144840A EC SP21044840 A ECSP21044840 A EC SP21044840A
Authority
EC
Ecuador
Prior art keywords
nucleic acids
produce
viral vectors
recombinant viral
cassettes
Prior art date
Application number
ECSENADI202144840A
Other languages
English (en)
Inventor
Darby Thomas
David Dismuke
Original Assignee
Stridebio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stridebio Inc filed Critical Stridebio Inc
Publication of ECSP21044840A publication Critical patent/ECSP21044840A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente se describen ácidos nucleicos, casetes de transferencia de AAV y plásmidos utilizados en la producción de vectores virales adenoasociados recombinantes (rAAV). Los ácidos nucleicos, casetes y plásmidos descritos comprenden secuencias que expresan uno o más transgenes que tienen eficacia terapéutica para mejorar, tratar y/o prevenir una o más enfermedades o trastornos.
ECSENADI202144840A 2018-11-21 2021-06-21 Vectores virales recombinantes y ácidos nucleicos para producirlos ECSP21044840A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862770202P 2018-11-21 2018-11-21

Publications (1)

Publication Number Publication Date
ECSP21044840A true ECSP21044840A (es) 2021-09-30

Family

ID=70773595

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202144840A ECSP21044840A (es) 2018-11-21 2021-06-21 Vectores virales recombinantes y ácidos nucleicos para producirlos

Country Status (20)

Country Link
US (1) US20210324418A1 (es)
EP (1) EP3883954A4 (es)
JP (1) JP2022508182A (es)
KR (1) KR20210103469A (es)
CN (1) CN113302201A (es)
AR (1) AR117145A1 (es)
AU (1) AU2019385506A1 (es)
BR (1) BR112021009733A2 (es)
CA (1) CA3120289A1 (es)
CL (1) CL2021001327A1 (es)
CO (1) CO2021008120A2 (es)
EA (1) EA202191418A1 (es)
EC (1) ECSP21044840A (es)
IL (1) IL283344A (es)
MX (1) MX2021005997A (es)
PE (1) PE20211419A1 (es)
PH (1) PH12021551155A1 (es)
SG (1) SG11202105326WA (es)
TW (1) TW202039533A (es)
WO (1) WO2020106916A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107686842A (zh) * 2016-08-03 2018-02-13 南京大学 一种靶多核苷酸编辑方法及其应用
JP7406677B2 (ja) 2018-04-03 2023-12-28 ギンコ バイオワークス インコーポレイテッド 抗体を回避するウイルスベクター
CA3157700A1 (en) 2019-10-17 2021-04-22 Stridebio, Inc. Adeno-associated viral vectors for treatment of niemann-pick disease type c
US20220010332A1 (en) * 2020-07-08 2022-01-13 Neuracle Genetics Inc. Intron fragments
WO2022026410A2 (en) * 2020-07-27 2022-02-03 Voyager Therapeutics, Inc Compositions and methods for the treatment of niemann-pick type c1 disease
WO2022072325A1 (en) * 2020-09-29 2022-04-07 NeuExcell Therapeutics Inc. Neurod1 combination vector
WO2022072309A1 (en) * 2020-09-29 2022-04-07 NeuExcell Therapeutics Inc. Ascl1 vector
AU2021355362A1 (en) * 2020-09-29 2023-05-11 NeuExcell Therapeutics Inc. Neurod1 vector
WO2023221942A1 (en) * 2022-05-16 2023-11-23 Shanghai Vitalgen Biopharma Co., Ltd. Recombinant aav vectors for treating glutaric aciduria type i
WO2023240162A1 (en) * 2022-06-08 2023-12-14 Scribe Therapeutics Inc. Aav vectors for gene editing
WO2024074143A1 (en) * 2022-10-08 2024-04-11 Lingyi Biotech Co., Ltd. Construct for enhancing gene expression

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090221620A1 (en) * 2008-02-20 2009-09-03 Celera Corporation Gentic polymorphisms associated with stroke, methods of detection and uses thereof
WO2015044704A1 (en) * 2013-09-30 2015-04-02 Sanofi Use of neuroglobin agonist for preventing or treating mitochondrial rcci and/or rcciii deficiency disease
EP3245221A4 (en) * 2015-01-16 2018-06-13 Voyager Therapeutics, Inc. Central nervous system targeting polynucleotides
WO2016150964A1 (en) * 2015-03-23 2016-09-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment and the prevention of neurological phenotype associated with friedreich ataxia
US11896651B2 (en) * 2015-05-16 2024-02-13 Genzyme Corporation Gene editing of deep intronic mutations
RU2021102893A (ru) * 2015-11-05 2021-03-03 Бамбу Терапьютикс, Инк. Модифицированные гены атаксии фридрейха и векторы для генной терапии
RU2742612C2 (ru) * 2015-12-15 2021-02-09 Джензим Корпорейшн Векторы на основе аденоассоциированного вируса для лечения муколипидоза типа ii
US20210254056A1 (en) * 2017-05-05 2021-08-19 Camp4 Therapeutics Corporation Identification and targeted modulation of gene signaling networks

Also Published As

Publication number Publication date
CL2021001327A1 (es) 2021-12-31
MX2021005997A (es) 2021-08-11
AR117145A1 (es) 2021-07-14
US20210324418A1 (en) 2021-10-21
PE20211419A1 (es) 2021-08-03
TW202039533A (zh) 2020-11-01
IL283344A (en) 2021-07-29
EP3883954A1 (en) 2021-09-29
CO2021008120A2 (es) 2021-08-09
KR20210103469A (ko) 2021-08-23
BR112021009733A2 (pt) 2022-01-04
EP3883954A4 (en) 2022-08-10
CN113302201A (zh) 2021-08-24
JP2022508182A (ja) 2022-01-19
PH12021551155A1 (en) 2021-11-03
SG11202105326WA (en) 2021-06-29
AU2019385506A1 (en) 2021-06-03
WO2020106916A1 (en) 2020-05-28
CA3120289A1 (en) 2020-05-28
EA202191418A1 (ru) 2021-08-05

Similar Documents

Publication Publication Date Title
ECSP21044840A (es) Vectores virales recombinantes y ácidos nucleicos para producirlos
CL2020003176A1 (es) Novedosas proteínas de la cápside del virus adenoasociado (divisional sol. 201900167).
CL2018000170A1 (es) Vectores de aav para la terapia génica de la retina y el snc (divisional de solicitud 201602713)
CL2018001522A1 (es) Focalización de péptidos para dirigir virus adenoasociados (aavs)
AR115097A1 (es) Vectores virales adenoasociados dirigidos al hígado
CL2018003196A1 (es) Cápsides variantes de virus adenoasociados y métodos de uso de estas.
BR112017007737A2 (pt) variantes de aav recombinantes e usos das mesmas
CO2018000134A2 (es) Factor ix modificado, y composiciones para la transferencia de genes a células, órganos y tejidos
CO2018012096A2 (es) Proteínas de fusión gdf15 y usos de estas
CO2017010831A2 (es) Adenovirus oncolítico que codifica una proteína b7
MX2018007234A (es) Vectores virales adenoasociados utiles en el tratamiento de atrofia muscular espinal.
CO2022004652A2 (es) Casete de transferencia de aav
DOP2016000237A (es) Terapia genica para la retinitis pigmentaria
CO2018012082A2 (es) Administración de vectores del virus adenoasociado de β-sarcoglicano y microarn-29 y el tratamiento de la distrofia muscular
WO2015158749A3 (de) Viraler vektor für den zielgerichteten gentransfer in gehirn und rückenmark
MX2019006722A (es) Construcciones de adenovirus de chimpance con antigenos de lyssavirus.
DK3740222T3 (da) Modificeret RAAV-capsidprotein til genterapi
BR112017005235A2 (pt) vetores virais adeno-associados para o tratamento de glaucoma de miocilina (myoc)
CO2021000914A2 (es) Productos y métodos de virus adenoasociado recombinante para el tratamiento de la distrofia muscular de cinturas 2a
CY1123312T1 (el) Aav-βασιζομενη γονιδιακη θεραπεια για σκληρυνση κατα πλακας
CL2022000939A1 (es) Vectores virales adenoasociados para el tratamiento de la enfermedad de niemann-pick tipo c
AR120252A1 (es) Casete de transferencia de aav
BR112017022621A2 (pt) liberação do gene de smad7 como uma substância terapêutica
EA201990955A1 (ru) Разработка капсидов aav